Procainamide Hydrochloride Injection
Product Images NDC 51662-1630

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Procainamide Hydrochloride (NDC 51662-1630). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pouch Labeling (51662 1360 2 Pouch Label)

Label for PROCAINAMIDE HYDROCHLORIDE injection, USP, 100 mg/mL 10 mL syringe. Includes NDC 51662-1630-2, lot number, expiration date 2030-01-01, and manufacturer HF Acquisition Co LLC, Mukilteo, WA. The label specifies use for IV infusions, ingredients including benzyl alcohol and sodium bisulfite as preservatives, storage instructions, and an RX only designation.*

FDA Label Image

Case Labeling (51662 1630 3 Case Label)

Label for PROCAINAMIDE HYDROCHLORIDE injection, USP, strength 100 mg/mL in 10 mL syringes, packaged as a case of 5. The label includes NDC 51662-1630-3, lot number 123456, and expiration date 2030-01-01. Manufactured by HF Acquisition Co LLC, DBA HealthFirst, Mukilteo, WA. The label specifies it is for intravenous infusion preparation only.*

FDA Label Image

Serialized Label (51662 1630 3 Serialized Labeling)

A close-up of a label on a pharmaceutical package for PROCAINAMIDE HYDROCHLORIDE injection by HF Acquisition Co LLC. The label includes barcode data and notes that the product is distributed by HF Acquisition Co LLC in Mukilteo, WA. Text advises users to see the manufacturer's package insert.*

FDA Label Image

Boxed Warning (Boxed Warning)

A warning text panel for procainamide hydrochloride injection that addresses the risk of developing a positive anti-nuclear antibody (ANA) test and symptoms of lupus erythematosus-like syndrome with prolonged administration, advising assessment of benefits versus risks for continued therapy.*

FDA Label Image

Carton (Carton Labeling)

Packaging label for PROCANAMIDE HYDROCHLORIDE injection, USP 100 mg/mL, with a total of 1000 mg per 10 mL in a Luer-Jet Luer-Lock prefilled syringe. The label shows instructions for syringe assembly with aseptic technique, storage conditions at 20° to 25°C, and warnings about solution color and glass breakage. The labeler is Amphastar Pharmaceuticals, part of INTERNATIONAL MEDICATION SYSTEMS, LIMITED, So. El Monte, CA.*

FDA Label Image

Dosage (Dosage And Admin)

A data table titled "Dilutions and Rates for Intravenous Infusions" for Procainamide Hydrochloride Injection, USP. It details final concentration, infusion volume, amount of procainamide hydrochloride to be added, and infusion rate for initial loading and maintenance infusions, including notes on infusion preparation and monitoring.*

FDA Label Image

How Supplied (How Supplied)

An instructional illustration showing three steps for using an injection vial and injector device. Step 1: Remove protective caps from the vial and injector. Step 2: Thread the vial into the injector three half turns until pierced by a metal cannula, with a warning not to push the vial into the injector to avoid misalignment. Step 3: Remove the cover and expel air before injection.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of Procainamide Hydrochloride showing its molecular arrangement with aromatic ring and associated chemical groups, including an amine and hydrochloride component.*

FDA Label Image

Syringe Label (Syringe Label)

Label for Procainamide Hydrochloride Injection USP, 100 mg/mL strength in a 10 mL volume vial. The label includes a measurement scale from 0 to 900 mg and contains the text Rx Only and warning about bisulfites. The labeler is IMS Limited, located in So. El Monte, CA, USA. Barcode and non-varnish area markings are also present.*

FDA Label Image

Warnings (Warnings)

This text panel discusses mortality data from the Cardiac Arrhythmia Suppression Trial (CAST) related to antiarrhythmic drugs, including procainamide hydrochloride, highlighting study results and clinical considerations. It also details blood dyscrasias such as agranulocytosis and bone marrow depression observed in patients treated with procainamide hydrochloride, including recommendations for monitoring blood counts and managing therapy.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.